The Healthcare Technology Report is pleased to announce The Top 50 Healthcare Technology Companies of 2025. This year revealed how quickly healthcare technology can deepen its impact, with notable advances in diagnostics, care delivery, and clinical intelligence. Viz.ai pushed intelligent automation further into frontline medicine in May with the launch of its Viz Oncology Suite and later followed with Viz Assist, a multimodal AI agent that supports real-time clinical reasoning. In August, Natera advanced precision medicine at scale by releasing AI foundation models trained on more than 250,000 tumor exomes and one million plasma timepoints—bringing population-level data to early detection and treatment planning.
The year also brought bold platform expansions and strategic consolidation. Spring Health broadened its global reach with major neurodiversity offerings and expanded pediatric evaluation capabilities for employers and health plans. Komodo Health released Marmot, a healthcare-native analytics engine producing transparent, verifiable insights in minutes, and partnered with Nasdaq to launch a new medical claims dataset for institutional investors. On the M&A front, Scientist.com agreed to be acquired by GHO Capital Partners, accelerating product innovation and global growth across its AI-enabled R&D marketplace.
These highlights represent only part of the progress made by this year’s awardees. Across digital care delivery, clinical insights, data platforms, and next-generation therapeutics, the companies on this list are advancing solutions that strengthen care quality and operational performance. Please join us in recognizing The Top 50 Healthcare Technology Companies of 2025.
Natera, a leader in cell-free DNA testing, develops diagnostics that help detect disease earlier and guide more personalized care. Its technology supports clinical applications in oncology, women’s health, and organ health, underpinned by one of the world’s largest cfDNA datasets.
Under the leadership of CEO Steve Chapman, Natera has expanded its molecular diagnostics footprint through continual innovation and clinical validation. The company’s tests have been featured in more than 300 peer-reviewed studies and are covered by Medicare for multiple conditions.
In Q2 2025, Natera reported $546.6 million in revenue, up 32% year over year, and processed over 850,000 tests. In August, Natera launched AI foundation models trained on more than 250,000 tumor exomes and 1 million plasma timepoints to support drug discovery and clinical decision-making.
Spring Health, founded in 2016 provides a precision mental health platform for employers, payers, and their members. Its model combines a proprietary assessment, machine-learning–guided care matching, and a Care Navigator that coordinates services ranging from digital exercises and coaching to therapy and medication management. The company now covers more than 20 million people across 40 countries and 20 languages.
In March 2025, Spring Health introduced a Neurodiversity Hub, expanded access to specialized therapists and coaches, launched 130 multilingual learning videos, and added rapid evaluations for pediatric and adolescent neuropsychology—advancing support for neurodivergent employees, families, and managers.
Co-Founder and CEO April Koh led the company in 2024 through a Series E funding round that valued Spring Health at $3.3 billion, enabling global expansion and an expanded provider network serving major employers including Microsoft, Target, JPMorgan Chase, and Delta Air Lines.
Agiliti delivers, maintains, and manages medical and surgical equipment for healthcare providers across the United States. The company supports more than 10,000 hospitals, surgery centers, and alternate care sites, ensuring reliable access to compliant, well-maintained devices.
With a workforce of over 5,500 employees, Agiliti oversees a broad range of assets—from infusion pumps and imaging systems to surgical tools—and offers clinical engineering and supply chain services that improve efficiency and control costs.
In 2025, Agiliti introduced Essentia™, a versatile, multi-acuity bed frame that can support patients across different clinical settings from Med-Surg to the ICU. Essentia offers caregivers the flexibility to tailor care based on patient risk profiles and features proprietary safety capabilities designed to help accelerate patient mobility and reduce risk to caregivers.
symplr, headquartered in Houston, Texas, develops enterprise healthcare operations software that streamlines administrative workflows and unifies critical data across hospitals, health plans, and post-acute providers. Built on Amazon Web Services, its cloud-based Operations Platform integrates workforce, provider data, quality, compliance, spend, and access management tools into a single, interoperable system that reduces vendor complexity and improves efficiency.
symplr strengthened its workforce management suite with the $75 million acquisition of AMN Healthcare’s Smart Square, an AI-driven nurse and staff scheduling solution featuring predictive analytics and real-time staffing capabilities, in July.
Backed by Clearlake Capital Group and Charlesbank Capital Partners, symplr serves 9 in 10 U.S. hospitals, more than 400 health plans, and 6,000 post-acute and senior living facilities. With Interim CEO and Board Member Chris Colpitts at the helm, the company continues to invest in automation and AI-powered analytics to help healthcare organizations reduce administrative burden, contain costs, and focus more time on patient care.
Included Health delivers a connected care experience integrating navigation, virtual and in-person services, behavioral health, and coordinated support. Formed in 2021 through the merger of Grand Rounds and Doctor On Demand, the company now serves millions of members across hundreds of employers, health plans, and government organizations. Notable partnerships include Walmart, providing virtual primary care for nearly a million associates, and CalPERS, through Blue Shield’s value-based plan.
Its model combines digital access with personalized guidance, making it easier for people to find high-quality, affordable care. Included Health has raised more than $500 million from investors such as The Carlyle Group, funding the expansion of one of the most comprehensive care delivery platforms in the U.S. Co-Founder and CEO Owen Tripp, who previously launched Reputation.com and Grand Rounds, has led the company to sustained growth and profitability.
LifeNet Health, founded in 1982, is a global regenerative medicine organization that develops transplant and biologic solutions to restore health and improve patient outcomes. Its offerings span organ recovery, tissue bio-implants, and cellular therapies.
The company’s proprietary Allowash sterilization process has enabled the distribution of more than 10 million allografts with no disease transmission. In August, LifeNet Health expanded its biologics portfolio with the acquisition of HCM Medical, a Netherlands-based manufacturer specializing in xenograft and implant technologies.
President and CEO Rony Thomas oversees the company’s growing research and manufacturing network across the U.S. and Europe. With more than four decades of experience and the industry’s longest-running AATB accreditation, LifeNet Health combines scientific innovation with a sustained commitment to donor and patient care.
Qualifacts provides electronic health record and data solutions purpose-built for behavioral health and human services organizations. Its platforms, Credible, CareLogic, and InSync, are used by more than 2,700 organizations across all 50 states, including one-third of the nation’s Certified Community Behavioral Health Centers (CCBHCs). The company’s software supports clinical, administrative, and financial operations for providers serving millions of individuals each year.
CEO Josh Schoeller, who joined with over 30 years of experience in healthcare data and software, has directed the expansion of the Qualifacts iQ suite of AI-powered tools, including iQ Assistant and iQ Agent, launched in 2025 to automate documentation, streamline onboarding, and reduce provider burnout.
Backed by Warburg Pincus since 2019, Qualifacts is advancing its interoperable, data-driven technology to help behavioral health agencies deliver whole-person care and improve operational and clinical outcomes.
Relias provides a connected workforce enablement platform that helps healthcare organizations improve staff performance, compliance, and patient outcomes. Headquartered in Morrisville, North Carolina, the company serves 12,000 organizations and 4.5 million caregivers worldwide.
CEO Kay Krafft leads Relias’ mission to help healthcare teams learn, perform, and thrive. The platform delivers 3,000 accredited courses alongside data-driven tools for competency tracking, quality improvement, and recruitment.
In March 2025, Relias acquired InceptionXR to integrate virtual reality training into its learning ecosystem. The immersive modules help clinicians practice infection prevention and clinical decision-making in realistic settings, enhancing both confidence and performance.
Komodo Health provides AI-powered healthcare intelligence built on its flagship Healthcare Map, which tracks more than 330 million de-identified U.S. patient journeys. The platform supports more than 50 therapeutic areas, helping life sciences companies, payers, providers, and advocacy groups close care gaps, improve outcomes, and accelerate access to therapies.
In August 2025, Komodo launched Marmot, a healthcare-native AI engine that delivers transparent, verifiable analytics in minutes and is already in use by pharmaceutical partners such as Alnylam. Earlier in the year, the company collaborated with Nasdaq to introduce the Medical Claims Insights dataset, providing financial institutions with visibility into payer, provider, and pharmaceutical trends.
Since its founding in 2014, Komodo has raised $514 million from investors including Tiger Global, Andreessen Horowitz, Dragoneer, and others. Co-Founder and CEO Arif Nathoo has led Komodo’s growth from a data-driven startup into one of the industry’s most influential platforms for real-world healthcare insights.
CareDx supports the transplant community with molecular diagnostics, software, and digital tools that help monitor graft health and guide patient care. Its flagship assays, AlloMap Heart and AlloSure, allow non-invasive rejection surveillance through donor-derived cell-free DNA, reducing the need for biopsies.
Reporting $86.7 million in Q2 2025 revenue and a 13% year-over-year rise in testing volumes, CareDx continues to expand globally. President and CEO John W. Hanna, who joined in 2024, has more than two decades of leadership in molecular diagnostics and life sciences. Before CareDx, he served as CEO of Apton Biosystems, later acquired by Pacific Biosciences, and spent ten years at Veracyte in senior commercial roles.
The California-based company also develops lab and software solutions for transplant centers and offers HLA typing technology that integrates with clinical workflows. In 2025, it earned EU IVDR certification for its AlloSeq Tx and QTYPE products and continued advancing molecular diagnostic tools for transplant care.
WCG (WIRB-Copernicus Group) accelerates and safeguards clinical research through technology, data, and expert support. The company partners with biopharma firms, CROs, academic institutions, and research sites to streamline trial operations and protect participants.
In May 2025, the company divested its electronic clinical outcomes assessment business to Clario to sharpen focus on core study optimization services. Under CEO Sam Srivastava, WCG continues to advance its mission to deliver faster, safer, and more effective clinical research globally.
With 55 years of experience, WCG supports over 4,000 clinical trials each year across 130 countries and contributes to over 90% of FDA-approved therapies. Its platform integrates study planning, site enablement, execution, and data intelligence to accelerate research while maintaining quality and compliance.
Aeroflow Health provides medical equipment, virtual care, and patient support that connect individuals, providers, and health plans. Founded in 2001 and based in Asheville, North Carolina, the company simplifies access to essential healthcare products through insurance, covering sleep therapy, urology, diabetes, breastfeeding, and incontinence.
In October 2025, the company partnered with UnitedHealthcare to expand virtual nutrition counseling nationwide, supporting preventive care and chronic disease management. Co-Founders Casey and Don Hite have grown Aeroflow into a national health-solutions provider serving more than 1 million patients each year.
Aeroflow combines technology with one-on-one guidance to help patients navigate insurance coverage, select products, and access educational resources. Its focus on accessibility and clear communication ensures patients receive the care and equipment they need with minimal barriers.
TG Therapeutics is a fully integrated biopharmaceutical company advancing novel therapies for B-cell diseases, with a focus on autoimmune disorders such as multiple sclerosis (MS). Its lead product, BRIUMVI® (ublituximab-xiiy), is a glycoengineered anti-CD20 monoclonal antibody approved in the U.S. and several global markets for adults with relapsing forms of MS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
In October, the company achieved a major milestone with the completion of enrollment in its Phase 3 ENHANCE trial, which evaluates a new, simplified dosing schedule consolidating BRIUMVI’s Day 1 and Day 15 infusions into a single treatment. The trial aims to maintain therapeutic exposure while improving convenience for patients and infusion centers. Building on this progress, TG Therapeutics raised its full-year global revenue target to $600 million.
Chairman, President, and CEO Michael S. Weiss, who founded the company, continues to steer TG Therapeutics’ development of next-generation therapies, including a subcutaneous formulation of ublituximab now in Phase 3 trials.
Phathom Pharmaceuticals, based in New Jersey, develops and commercializes treatments for acid-related gastrointestinal disorders. The company holds exclusive rights in the U.S., Europe, and Canada to a potassium-competitive acid blocker (PCAB) that provides a next-generation approach to acid suppression.
Under CEO Steven Basta, Phathom advanced from clinical development to commercialization with VOQUEZNA, including its TRIPLE PAK and DUAL PAK formulations. Since launch, more than 580,000 prescriptions have been filled, supported by broad payer coverage and growing prescriber adoption.
Phathom reported Q2 2025 revenue of $39.5 million and projects full-year revenue of $165–$175 million, with profitability expected in 2026. With 10-year FDA New Chemical Entity exclusivity through 2032, the company is expanding its GI portfolio and reinforcing its position in acid suppression therapy.
Welldoc, headquartered in Columbia, Maryland, develops AI-powered digital health solutions for managing cardiometabolic conditions in real time. Its FDA-cleared platform supports patients with diabetes, hypertension, heart failure, and obesity, while also integrating mental wellbeing and sleep tracking.
Welldoc’s global team, led by President and CEO Kevin McRaith, builds AI systems that translate complex health data into practical guidance for patients and clinicians. Operating from the U.S. and India, the company refines its models through millions of user interactions, continually improving care coordination and cost efficiency.
In June 2025, Welldoc extended its partnership with Eli Lilly to power the Lilly Health app for patients using incretin therapies such as Zepbound and Mounjaro, offering a personalized experience for tracking medication, behavior, and progress.
Biodesix develops diagnostic tests and services focused on lung disease. Its two core offerings are Biodesix Diagnostic Tests, marketed as Nodify Lung and IQLung, and Biodesix Development Services for biopharma and life sciences partners.
The company operates two accredited clinical laboratories and an FDA cGMP-registered manufacturing facility. Its multi-omic platform combines proteomic and genomic analysis to enable precision diagnostics from sample extraction through molecular interpretation.
In Q3 2025, Biodesix reported a 20% year-over-year increase in revenue and an 81% gross margin, reflecting continued demand for its diagnostic portfolio. Under President and CEO Scott Hutton, the company is advancing accessible, timely testing that helps physicians personalize care and improve outcomes for patients with lung disease.
Viz.ai, founded by neurosurgeon Dr. Chris Mansi and machine learning expert Dr. David Golan, applies artificial intelligence to accelerate diagnosis, coordination, and treatment across major disease areas. Its goal is to reduce delays in care through intelligent automation, giving specialists real-time insights to act faster.
The company expanded into cancer care in May 2025 with the Viz Oncology Suite, an end-to-end AI platform designed to speed diagnosis and coordination for oncology teams. Later in the year, it introduced Viz Assist, the first multimodal AI agent platform that combines imaging, EHR, and ambient listening data to deliver autonomous, real-time clinical insights. Backed by Tiger Global, Insight Partners, Kleiner Perkins, GV, and Greenoaks Capital, Viz.ai has raised over $100 million and achieved a $1.2 billion valuation.
Trusted by more than 1,800 hospitals and health systems across the U.S. and Europe, Viz.ai’s AI-powered Viz One platform integrates imaging, EHR, and communication tools to identify suspected disease, alert specialists in real time, and streamline decision-making across multidisciplinary teams. Its FDA-cleared and CE-marked algorithms now support clinical workflows spanning stroke, cardiology, trauma, oncology, and radiology, helping providers act faster and more precisely.
Nym uses natural language understanding to automate medical coding, turning unstructured clinical notes into accurate billing codes in seconds. Its fully autonomous system improves accuracy and speeds up reimbursement, allowing clinicians to focus on patient care rather than paperwork.
The company’s technology now processes more than 6 million charts a year across 300 U.S. healthcare facilities, spanning specialties such as emergency medicine, radiology, and outpatient surgery. In late 2024, Nym raised a growth funding round led by PSG, with participation from Google Ventures, Addition, and Samsung Next, to accelerate platform innovation and expand its reach.
CEO Or Peles, a former NICE Actimize and Tasq.ai executive, leads a multidisciplinary team of clinicians, engineers, and linguists working to make medical documentation more efficient and transparent.
Led by CEO Mike Alvarez, Glooko offers a connected care platform that enables individuals to manage diabetes and other chronic conditions by integrating real-time data. The Palo Alto-based company unifies information from more than 200 glucose meters, insulin pumps, and continuous glucose monitors.
Its technology integrates with electronic health records to give clinicians and patients actionable insights that simplify care and improve outcomes. Glooko’s platform supports more than 4.4 million users and 10,000 healthcare providers across 30 countries.
Glooko expanded into inpatient care by acquiring Monarch Medical Technologies in September 2025, developer of the EndoTool Glucose Management System for hospital use. Backed by investors such as Georgian, Canaan Partners, Health Catalyst Capital, and Mayo Ventures, the company raised $100 million in Series F funding in 2024.
Omnicell provides automated medication management and pharmacy intelligence solutions that improve safety, efficiency, and outcomes across healthcare systems. Founded in 1992 and based in Fort Worth, Texas, the company supports hospitals and clinics worldwide through robotics, analytics, and connected services.
Chairman, President, and CEO Randall Lipps founded Omnicell after witnessing inefficiencies in hospital supply management. Under his leadership, the company has evolved from a single product to a full automation ecosystem advancing the “Autonomous Pharmacy” vision.
Omnicell reported quarterly revenue of $311 million in 2025, a 10% increase year over year, driven by growth in connected devices and services. The company continues to innovate in IV compounding, outpatient pharmacy, and medication tracking, helping healthcare organizations deliver safer, more precise care.
Loftware is a global provider of product identification software, offering labeling, artwork management, and connected-packaging on a single cloud platform. The company serves more than 100,000 customers and 1,000 partners across 100+ countries, generating over 51 billion labels annually and helping brands in industries such as pharmaceuticals and medical devices.
In April 2025, Loftware expanded its capabilities with the acquisition of BL.INK, adding enterprise link management, dynamic QR codes, GS1 Digital Link, and no-code Digital Product Passports to power connected packaging and consumer engagement. The company’s growth has been supported by private-equity backers Riverside Partners since 2014 and Accel-KKR, which joined in 2023, enabling global expansion and multiple strategic acquisitions.
Chief Executive Officer Jim Bureau, who previously held leadership roles at JAGGAER and Verint, directs Loftware’s strategy to modernize product identification from new product development through manufacturing and distribution to consumer touchpoints. With certified integrations to SAP, Oracle, and Infor, Loftware positions its platform as the single system of record for labeling and packaging across complex, regulated supply chains.
Consensus Cloud Solutions offers secure, compliant data exchange platforms for regulated industries including healthcare, finance, and government. The company enhances digital workflows specifically for the healthcare sector with AI-powered intelligent data extraction and transformation. Chief Executive Officer Scott Turicchi, formerly president and CFO of J2 Global, brings more than two decades of operational and financial leadership as the company expands its role in secure, intelligent data exchange.
Originally part of J2 Global, Consensus became independent following its 2021 spinoff and IPO. With roots in eFax®, the company has evolved from digital faxing to enterprise-grade interoperability and workflow automation. In July 2025, it secured a $225 million credit facility to strengthen liquidity and streamline operations. During the second quarter, Consensus reported $87.7 million in revenue and a 54.8% adjusted EBITDA margin.
Backed by its long history in communications technology, Consensus continues to build modern infrastructure that connects healthcare organizations and other regulated sectors through compliant, AI-driven data exchange.
PartsSource operates one of the largest B2B marketplaces and supply chain software platforms in healthcare, connecting over 5,000 hospitals, 15,000 clinical sites, and 6,000 OEMs and suppliers. Its evidence-based technology supports procurement, vendor management, and asset optimization for more than four million mission-critical products and services.
Under the leadership of Philip Settimi, MSE, MD, President and CEO since 2014, PartsSource has steadily expanded its capabilities to improve asset uptime and operational resilience across healthcare systems. With Bain Capital Private Equity as majority investor since 2021, the company has accelerated innovation through strategic acquisitions such as Glassbeam, an analytics leader in medical equipment performance, and NVRT Labs, a developer of virtual reality training.
In June, the company advanced its Asset Uptime initiative to reduce downtime and improve utilization. Complementing this, its PartsSource PRO platform continues to deliver end-to-end solutions for asset management, workforce training, and evidence-based decision-making, helping health systems achieve greater efficiency and reliability in clinical operations.
TriNetX is a global health technology company operating the world’s largest federated real-world data network, connecting life sciences organizations and healthcare providers across more than 25 countries. Its platform gives users on-demand access to de-identified EHR and claims data, enabling millions of monthly research queries that accelerate clinical trial design, feasibility, and real-world evidence generation.
TriNetX’s network includes partnerships with 9 of the top 15 global pharmaceutical companies, such as Pfizer, Sanofi, and Novartis, and hundreds of healthcare organizations worldwide. The company has raised over $100 million across multiple funding rounds, including a Series D in 2024 led by Merck Global Health Innovation Fund, with participation from Mitsui, ITOCHU, Deerfield, and MPM Capital. In 2020, The Carlyle Group became TriNetX’s majority owner, driving continued international expansion and investments in AI, machine learning, and digital clinical trials.
Under founding CEO Gadi Lachman, who transitioned to a board role in 2025, TriNetX has become a central infrastructure for real-world data, empowering the global research community to connect, collaborate, and improve human health at scale.
Cleerly, headquartered in Denver and founded by cardiologist James K. Min, MD, develops AI-powered cardiovascular imaging that enables non-invasive detection and quantification of heart disease. Its technology provides comprehensive, plaque-based assessments of coronary artery disease through advanced CT analysis.
Built on nearly two decades of clinical research, Cleerly’s platform is FDA-cleared, Medicare-covered, and supported by a Category I CPT code for advanced plaque evaluation. These capabilities give physicians earlier visibility into disease progression and support more personalized care for patients at risk of heart attack.
In December 2024, Cleerly raised $106 million in Series C funding led by Insight Partners with participation from Battery Ventures and other existing investors. Under Dr. Min’s leadership, the company is setting a benchmark for precision cardiovascular diagnostics through data-driven, clinically validated insights.
PHC Corporation of North America (PHCNA) provides laboratory technologies that advance research in cell and gene therapy, biopharmaceutical development, and regenerative medicine. As part of the Biomedical Division of PHC Corporation and a member of Japan-based PHC Group, PHCNA manufactures and distributes PHCbi brand equipment across the U.S., Canada, and Latin America, supporting scientific institutions with high-precision preservation, incubation, and monitoring systems.
In March 2025, PHC collaborated with Cyfuse Biomedical to develop a real-time monitoring system for 3D cell products, marking a key advance in scalable cell therapy manufacturing. The technology integrates PHC’s LiCellGrow™ cell expansion system with Cyfuse’s Bio 3D Printing platform to improve cell stability and consistency during cultivation. Headquartered in Wood Dale, Illinois, PHCNA continues a legacy that began with Sanyo’s first pharmaceutical-grade refrigerator in 1966 and evolved through Panasonic Healthcare.
TechMatter, founded in 2017 and headquartered in Glendale, California, provides technology and operational infrastructure for healthcare organizations through managed IT services, enterprise software development, and revenue cycle systems. The company supports providers, hospitals, and billing groups with capabilities spanning electronic health records, practice management, cloud hosting, and workflow automation.
In August 2025, the company strengthened its revenue cycle capabilities through RCM Matter, its billing subsidiary, which introduced a next-generation RCM platform featuring automation, audit-ready documentation, and seamless EHR integration. Later in October, TechMatter launched Cure AR, an AI-enabled medical billing system designed to reduce denials, accelerate reimbursements, and improve financial visibility for healthcare practices.
Led by CEO and Founder Mubashir Hanif, TechMatter continues developing interoperable systems that support healthcare organizations’ clinical and administrative operations across the United States.
Founded in 1969 and headquartered in Tokyo, Japan, PHC Group is a global healthcare company dedicated to improving health through precision and digital technology. Operating through its network of subsidiaries, PHC Corporation, Ascensia Diabetes Care, Epredia, LSI Medience, Mediford, and Wemex, the PHC Group develops and delivers solutions across diagnostics, life sciences, diabetes management, and healthcare IT. Its products and services reach more than 125 countries, supported by 9,000 employees across 86 global companies.
In 2024, the company achieved profitability and continued expanding innovation through launches such as the LiCellMo live cell metabolic analyzer and the FDA-cleared Eversense 365 continuous glucose monitoring system. Under President and CEO Kyoko Deguchi, who assumed leadership in April 2024, PHC introduced a renewed Value Creation Plan emphasizing growth in diagnostics and life sciences and uniting its diverse businesses under the “One PHC” strategy.
With consolidated FY2024 revenues of ¥361.6 billion and a focus on sustainable, evidence-based innovation, PHC continues to strengthen its role as a trusted partner in research, diagnosis, treatment, and disease prevention worldwide.
Arcturus Therapeutics develops RNA-based medicines for rare diseases and infectious conditions. The company applies its proprietary LUNAR lipid delivery and STARR self-amplifying mRNA (sa-mRNA) technologies to create next-generation therapeutics and vaccines.
Arcturus developed KOSTAIVE, the world’s first approved self-amplifying mRNA COVID-19 vaccine, and partners with CSL Seqirus to advance mRNA vaccines for COVID-19 and influenza. President and CEO Joseph Payne oversees a portfolio of more than 500 global patents and an expanding pipeline of mRNA and sa-mRNA programs targeting vaccines, rare diseases, and gene-based therapies.
SMC is a global contract manufacturer specializing exclusively in healthcare. The company provides end-to-end solutions for the medical device, diagnostics, and pharmaceutical industries. This includes design and engineering, thermoplastic and liquid silicone injection molding, micro-molding, automation, assembly, packaging, labeling, sterilization, and full supply chain management.
Under the leadership of CEO Chetan N. Patel, SMC has grown from a regional plastics manufacturer into a trusted strategic partner for healthcare innovators worldwide. Through subsidiaries such as Oval Medical Technologies, SMC is also advancing next-generation autoinjector platforms for complex and viscous drug formulations.
With facilities across the United States, Costa Rica, India, and the United Kingdom, SMC operates ISO 13485–certified sites featuring Class 7 and 8 cleanrooms and advanced white-room manufacturing environments. Its agile, vertically integrated model allows customers to accelerate product development and scale production efficiently while maintaining regulatory compliance and consistent quality across global markets.
For more than half a century, Burlington Medical has designed and manufactured radiation protection gear for healthcare professionals worldwide. From its Virginia headquarters, the company supplies hospitals and imaging centers with protective garments, eyewear, gloves, barriers, and drapes built for long-term safety and comfort.
Its proprietary Xenolite material, both lead and PVC-free, has become central to its innovation, offering lightweight yet durable protection. Burlington also stands out as the only major manufacturer providing fully tailored radiation garments, individually measured for fit and weight distribution.
In January, Burlington unified operations with its UK subsidiary, ProtecX, creating one brand under a single global identity to strengthen product consistency and streamline manufacturing across regions. Chief Executive Officer Lee Ann Fachko, who joined in 2022 after senior roles in the medical device sector, steers the company toward practical, clinician-focused innovation.
August Bioservices is a contract development and manufacturing organization (CDMO) specializing in sterile injectable pharmaceuticals. The Nashville-based company provides formulation development, analytical testing, aseptic and terminal filling, inspection, labeling, and large-scale production services. The company is led by CEO Jenn Adams, a veteran of sterile injectable manufacturing.
August Bioservices partners with more than 40 pharmaceutical and biotech clients, offering dependable U.S.-based capacity as demand for domestic manufacturing grows. Backed by Oak HC/FT and Polaris Partners, the company raised a $65 million Series B round in 2024 to expand its high-speed vial filling and downstream automation. Between 2023 and 2024, revenue increased 77% to more than $70 million, and a $64.7 million expansion now underway in Nashville is expected to double output and workforce by 2026.
CliniComp’s mission is to deliver a comprehensive, reliable, and adaptable Electronic Health Record Solution Suite that transforms the healthcare experience for both provider and patient. In 1983, the company began with a vision to improve medical information systems for better patient care. CliniComp’s team carries on that vision and continues to be comprised of passionate innovators who push the status quo and believe in the power of harnessing technology to enhance the clinician and consumer journey throughout the care continuum.
CliniComp is dedicated to continuous advancement, customized delivery and transparent services to provide every human being the best and most coherent care imaginable. With unparalleled service, unmatched performance, and customized delivery, CliniComp elevates industry standards to provide a better healthcare experience for all.
Founded in 1983 by Chris Haudenschild, CliniComp was among the earliest developers of large-scale clinical information systems and remains the exclusive inpatient system provider for U.S. Department of Defense hospitals in the National Capital Region. Still independently owned, the company stays close to its founding mission of evolving clinician-driven healthcare technology through steady, practical innovation.
Recuro Health is an integrated digital health company providing a personalized, proactive approach to virtual care. Recuro’s virtual-first care platform enables patients to access comprehensive healthcare services, anytime, anywhere, through a single, customizable interface.
The company serves millions of members nationwide across all 50 states, offering core virtual services in primary care, behavioral health, and urgent care, along with supplemental benefits such as pharmacy, care management, advocacy, and physician locator tools. This model allows employers, payers, and individuals to tailor digital health solutions to meet specific population needs.
Chairman and CEO Phil Fasano, formerly a senior executive at Kaiser Permanente, helped scale that organization’s first telehealth program to 14 million members. At Recuro, he is leading efforts to expand access and integration across the digital health ecosystem, combining technology and clinical expertise to make coordinated, high-quality care available to patients wherever they are.
Simple is a digital health company that helps users achieve sustainable weight loss and long-term wellness through AI-guided coaching and evidence-based nutrition guidance. Co-founded by CEO Mike Prytkov in 2019, the company developed the Simple Life app, which began as an intermittent fasting tool and has evolved into a comprehensive program addressing nutrition, exercise, hydration, and behavior change.
The app personalizes each user’s plan through science-backed coaching, AI guidance, and daily support tailored to individual circumstances. Its gamified approach—featuring habit streaks, interactive prompts from its AI coach Avo, and gradual behavior reinforcement—promotes consistency and long-term results. Simple has surpassed 20 million downloads and achieved over $100 million in annual revenue, reflecting its growing presence among consumer health platforms.
OCuSOFT develops and supplies eye and skin care products designed to improve ocular surface health. The Texas-based company introduced OCuSOFT Lid Scrub, the first commercial eyelid cleanser, and established eyelid hygiene as a new care category.
Directed by CEO and Co-Chairman Cynthia Barratt and Co-Founder Nat Adkins, OCuSOFT’s portfolio includes ophthalmic, dermatologic, and professional products. Its innovations range from leave-on cleansers to topical anesthetics and supplements that enhance botulinum toxin results.
In October 2025, OCuSOFT partnered with NORWOOD Device & Diagnostics to connect diagnostic imaging and dry-eye therapies, offering a complete “diagnosis-to-treatment” model. Guided by its mission to meet clinical needs through innovation and quality, the company remains a trusted global partner for healthcare professionals.
ScienceSoft is a global IT consulting and software development firm specializing in healthcare and financial technology. With more than 750 professionals and over 4,000 completed projects, ScienceSoft delivers secure, scalable solutions across telemedicine, diagnostics, patient monitoring, PHI exchange, and analytics. It supports 1,300+ clients worldwide, including Rivanna Medical, ScribeAmerica, and Delaware Valley Community Health.
In July 2025, ScienceSoft introduced a HIPAA-compliant AI scheduling assistant built on Amazon’s Nova Sonic model, the first to offer real-time, bidirectional voice interaction. With 36 years of experience, the company is committed to transparency, reliability, and compliance.
CEO Nick Kurayev, who joined the company in 1997, has helped ScienceSoft to evolve from a software product firm into a full-service technology partner. The company maintains strategic partnerships with Microsoft, AWS, and Oracle, enabling it to support complex digital transformation, data integration, and cloud initiatives.
Angle Health offers full stack healthcare benefit solutions designed for SMB employers and health insurance brokers. Using the power of data and AI, the company’s former Palantir co-founders are rebuilding health benefits from the ground up.
At its core, Angle’s AI-powered platform enables employers to stabilize healthcare costs and customize their benefits to fit their employee needs. Using proprietary AI models trained on millions of de-identified patient records, Angle Health enables highly accurate, level-funded quotes in minutes rather than weeks.
This precision not only reduces underwriting variance by up to 30% compared to industry norms, but also unlocks coverage options for groups as small as two employees, segments long considered uninsurable. By combining advanced data analytics with a seamless experience for brokers, the company is redefining how organizations and their employees access healthcare benefits.
Clearwave builds patient revenue and engagement platforms that streamline scheduling, registration, eligibility, and payment for healthcare practices. Its connected system supports more than 500 specialty practices and 17,000 physicians, helping reduce administrative workload, accelerate collections, and strengthen patient retention.
Based in Atlanta, the company’s self-service technology now reaches more than 170 million patients, enabling many practices to automate up to 87% of registration tasks. In the first half of 2025 alone, 22 million patients used Clearwave’s platform. Earlier that year, the company expanded its clearwaveCARE program to deliver hands-on onboarding, training, and support, while a partnership with Valer extended its capabilities in patient communication and follow-up.
Backed by Great Hill Partners and Frontier Growth, Clearwave continues to scale as one of the major platforms driving self-service patient revenue optimization. Mike Coffey, appointed CEO in September 2025 after leading multiple tech-enabled growth companies including DTiQ and Zonar, is guiding the company’s next phase of innovation and customer-focused growth.
Scientist.com is an AI-enabled R&D orchestration platform used by many of the world’s largest pharmaceutical companies, hundreds of biotech firms, and thousands of pre-qualified suppliers. The platform unifies supplier discovery, bidding, contracting, compliance, and spend analytics, helping teams reduce cycle times, improve governance, and gain clearer budget visibility across preclinical and clinical work. The company’s mission is to modernize outsourced research so scientists can design better studies, source trusted partners quickly, and advance therapies with stronger transparency and control.
The company recently completed an acquisition by GHO Capital Partners LLP, a leading specialist healthcare investment advisor headquartered in London, to accelerate global expansion and product innovation. Scientist.com’s platform combines proprietary AI and embedded compliance frameworks to streamline outsourced research—from intelligent vendor matching and automated contracting to predictive modeling and negotiation support. This operating model allows sponsors to build private marketplaces and shorten processes that once took months to just days.
Elucent Medical develops precision-guided surgical technologies that enhance soft-tissue oncologic surgery. The company’s EnVisio Surgical Navigation System transforms standard tools into spatially aware instruments, giving surgeons real-time, 3D guidance during tumor excision.
Its ecosystem includes SmartClip wireless markers, SmartSensors, and SmartSupport, a virtual and in-person support platform that provides live procedural assistance. Together, these solutions improve surgical accuracy, workflow efficiency, and confidence in achieving clean margins.
Elucent raised a Series C round in 2024, followed by additional growth capital from Trinity Capital in early 2025. President and CEO Jason Pesterfield, a medtech veteran with three decades of leadership experience, leads the company’s work in advancing precision surgery through innovation in spatial intelligence and procedural support.
Verantos advances real-world evidence generation through artificial intelligence, producing high-validity data for clinical, regulatory, and reimbursement use. By combining structured and unstructured healthcare information, the company delivers research-grade insights that meet the rigor required by pharmaceutical companies and public health agencies.
Overseen by Founder and CEO Dr. Dan Riskin, a surgeon and healthcare AI expert, Verantos collaborates with organizations such as the FDA, NIH, and National Science Foundation, as well as leading biotechnology companies and academic medical centers. The company’s proprietary Evidence Platform and Research Network enable life sciences researchers to design credible, large-scale studies across therapeutic areas like cardiometabolic disease, immunology, and neuroscience.
Verantos launched its Alzheimer’s Disease Pragmatic Registry in July 2024, a first-of-its-kind dataset that combines structured EHR and claims information with unstructured clinical narratives and imaging reports, offering new insights into disease progression and treatment effectiveness.
Chief Executive Officer Yann Gaston-Mathé founded Iktos in 2016 with the goal of rethinking small-molecule drug discovery through artificial intelligence and robotics. Based in Paris, the company combines generative AI for molecular design with automated synthesis tools, shortening the path from concept to compound.
Its integrated platform—spanning Makya for molecule generation, Spaya for retrosynthesis, and Iktos Robotics—underpins more than 50 collaborations with pharmaceutical and biotech partners. In 2024, Iktos expanded its capabilities with the acquisition of Synsight, adding AI-driven biology to address complex protein and RNA interactions. By merging design, synthesis, and biological insight, Iktos continues advancing AI as a practical engine for faster, more efficient drug development.
Founded in 2014 as a spinout from Johns Hopkins University, Scene Health (formerly emocha Health) develops technology that helps patients stay consistent with their medications through daily video engagement and personalized coaching. Headquartered in Baltimore, Maryland, the company’s mobile-based “MedEngagement” program delivers personalized video coaching and daily check-ins with pharmacists, nurses, and health coaches, helping patients build lasting adherence habits and improve long-term health outcomes.
Co-Founder and CEO Sebastian Seiguer has guided the company toward significant milestones, including 1 million video check-ins completed and 25 peer-reviewed studies validating its approach.
Scene Health’s 360° care model modernizes Directly Observed Therapy, the gold standard for medication adherence, making it scalable across chronic and infectious diseases. Its platform supports over 120 customers and 720 partners across the healthcare ecosystem, including Medicaid and Medicare plans, public health departments, and health systems.
Home Medical Management (HMM) is a Madrid-based digital health company transforming how home healthcare is coordinated and delivered. Founded in 2018 by Diego Gerosa, who serves as Founder and Principal Chief Executive Officer, HMM connects patients, families, providers, payers, and healthcare professionals through a unified digital platform.
The company’s system integrates scheduling, geolocation, electronic prescriptions, AI-assisted coordination, and access to shared medical records in real time. Designed for payers, hospitals, and government agencies, it improves efficiency, transparency, and safety while maintaining strict compliance with ISO, GDPR, and HIPAA standards.
HMM supports more than 600,000 home visits annually and a network of 1,500 professionals worldwide. Its model has achieved measurable results—up to 50% cost savings, 96% patient satisfaction, and a 4.6% rehospitalization rate—making it a key digital infrastructure for coordinated home care.
Engitix Therapeutics develops next-generation treatments for fibrosis and solid tumors using its proprietary human extracellular matrix (ECM) platform. Founded in 2016, the company builds disease models that replicate the human microenvironment, improving translational accuracy in drug discovery.
The platform underpins programs in liver and gastrointestinal fibrosis and oncology indications including pancreatic and hepatocellular carcinoma. Engitix also collaborates with Takeda Pharmaceuticals on fibrotic liver and bowel diseases and with Dompé Farmaceutici to integrate ECM biology with AI-driven drug discovery.
Co-Founder and CEO Dr. Giuseppe Mazza leads the company’s work at the intersection of ECM biology, bioinformatics, and machine learning, advancing new therapeutic targets and de-risking drug development. The company is backed by investors including Netherton Investments and Dompé.
AmplifyMD is a virtual-care technology company that helps hospitals and health systems expand specialty coverage through an AI-enabled, EHR-integrated platform and a network of specialists across 15+ fields. Founded in 2019, the company provides the intelligent infrastructure behind modern TeleStroke, TeleHospitalist, TelePsychiatry, TeleNeurology, TeleCardiology, and other virtual specialty programs.
AmpplifyMD automates the entire virtual-consult workflow, from smart assignment to documentation, while deep EHR integrations keep onsite teams in their existing workflows and give remote physicians instant access to essential patient data. Real-time analytics offer visibility into demand, utilization, and throughput, enabling continuous improvement and stronger ROI across virtual-care programs.
Co-Founder and CEO Meena Mallipeddi leads the company’s mission to help health systems deliver timely specialty care in ways that reduce transfers, increase access across sites, and drive stronger clinical and financial performance.
XpertDox develops AI-based tools for medical coding, data analytics, and operational intelligence. Its technology automates revenue cycle workflows, improves clinical documentation accuracy, and provides healthcare organizations with clearer financial visibility.
XpertDox partnered with Nao Medical in January of this year, a New York-based multi-specialty healthcare provider, to integrate its AI medical coding and analytics systems. Co-Founder and CEO Dr. Sameer Ather, a physician-scientist, leads XpertDox’s work at the intersection of clinical practice and artificial intelligence.
At the core of the company’s offerings is XpertCoding, an AI-powered medical coding platform that automates and enhances coding accuracy while integrating with a proprietary Business Intelligence Platform to provide real-time insights. These tools help healthcare providers reduce claim denials, accelerate reimbursements, and achieve greater workflow compliance.
MDI Health applies artificial intelligence to medication management, helping payers and providers optimize treatment plans and reduce preventable drug-related harm. Its AI platform analyzes thousands of patient-specific factors to recommend clinically sound, cost-effective medication adjustments.
The company’s technology is used nationwide to improve STAR ratings, lower adverse-event risk, and reduce polypharmacy. In September of this year, MDI Health launched a research collaboration with Stanford Medicine’s Healthcare AI Applied Research Team to validate its algorithms.
CEO Brad Margolis, a veteran of multiple healthcare technology companies, is steering MDI Health’s expansion as medication management becomes an increasingly critical part of value-based care.
Immunis is developing biologic therapies aimed at reversing age-related immune decline and muscle loss. Its lead candidate, IMM01-STEM, is a stem-cell-derived secretome that contains natural immunomodulators to restore immune balance and promote tissue regeneration.
The therapy is currently in Phase 2 trials for sarcopenic obesity after early studies showed safety and improvements in gait speed and muscle function among older adults. Preclinical results have also indicated benefits in reversing muscle wasting and fat accumulation.
In early 2025, Immunis raised Series A-1 funding from Remiges Ventures, Continuum Health Ventures, and BOLD Capital Partners to advance clinical programs and expand research. Chairman Dr. Hans Keirstead, a neuroscientist and biotech entrepreneur, leads the company’s strategy in regenerative immunology.
Imagene AI was founded in Israel in 2020 by Dean Bitan, Jonathan Zalach, and Shahar Porat to decode tumor biology directly from pathology slides through artificial intelligence. Its models analyze digital slides, genomics, and clinical data to deliver near-real-time insights that support oncologists in diagnosis and treatment selection.
The company’s Oncology Intelligence Suite is used by hospitals and research centers to accelerate biomarker discovery and clinical development. In September, Imagene expanded its collaboration with Sheba Medical Center to apply multimodal foundation models across more than 3.5 million digitized slides and associated omics records. Under Bitan’s leadership as CEO, Imagene is focused on advancing precision oncology through computational scale, bringing AI-driven interpretation of cancer biology closer to everyday clinical use.
SimpleTherapy delivers musculoskeletal (MSK) and behavioral health solutions that blend AI-guided digital care with virtual and in-person provider networks. Founded in 2011 by orthopedic physicians and physical therapists, the company helps individuals manage pain, improve mobility, and reduce healthcare costs through evidence-based recovery programs and unified care delivery.
In 2022, SimpleTherapy broadened its scope through the Halcyon Behavioral and PhysMetrics merger and acquisition, creating a platform that integrates physical and behavioral health into a single experience. Today, it partners with employers, health plans, and Fortune 50 companies to support workforce well-being through accessible, personalized care.
The company is headquartered in Sunnyvale, California and led by Co-Founder and CEO Arpit Khemka, who has guided its evolution from an AI-driven physical therapy platform into a comprehensive digital health organization.
Cognivia develops analytical tools that integrate psychology and machine learning to improve the accuracy and efficiency of clinical trials. Founded in 2013 and based in Belgium, the company helps pharmaceutical sponsors reduce variability and enhance trial success rates by quantifying how patient behavior influences outcomes.
CEO Dominique Demolle, PhD, a former Eli Lilly executive, leads the company’s mission to integrate patient psychology into modern drug development and healthcare decision-making. Cognivia’s patented methods combine behavioral science with predictive analytics to clarify how psychological factors affect treatment effect.
Its flagship technology, Placebell, models individual placebo responses across therapeutic areas, reducing trial variability by up to 30% and shortening study timelines without compromising statistical power.
Jelvix, founded in 2011 and headquartered in Estonia, provides custom software engineering, IT consulting, and digital transformation services for sectors including healthcare, finance, insurance, and real estate. The company employs more than 450 specialists across Europe, North America, and Asia.
With expertise spanning enterprise software, SaaS, data engineering, and mobile app development, Jelvix delivers secure, scalable solutions backed by ISO 9001 and ISO 27001 certifications. Its teams help healthcare providers and enterprises modernize infrastructure and manage data more efficiently.
In October 2025, Jelvix expanded its corporate social responsibility initiative to help hospitals and clinics strengthen cybersecurity, offering free tools and training to mitigate medical data breaches. Co-Founder and CEO Sasha Andrieiev has overseen Jelvix’s evolution into a global engineering partner for enterprises, shaping its approach to secure, responsible innovation in healthcare technology.
link